Clinicophysiological outcomes after total pancreatectomy. (1st December 2016)

• Record Type: Journal Article
• Authors: Suzuki, Shuji; Miura, Junnosuke; Shimizu, Kyoko; Tokushige, Katsutoshi; Uchigata, Yasuko; Yamamoto, Masakazu
• Is Part Of: Scandinavian journal of gastroenterology. Volume 51:Number 12(2016)
• Page Start: 1526
• Page End: 1531
• Publication Date: 2016-12-01
• Subjects: Total pancreatectomy -- pancreatic neoplasms -- glycemic control -- synthetic insulin -- pancreatic enzyme; Gastroenterology -- Periodicals; Digestive organs -- Diseases -- Periodicals; 616.33
• DOI: 10.1080/00365521.2016.1211173
• Languages: English
• ISSNs: 0036-5521

Abstract

Abstract: Purpose: Total pancreatectomy (TP) for pancreatic neoplasms is associated with high morbidity and mortality rates. However, with recent advances in surgical techniques and improved postoperative management, the number of cases with clinical indications for TP is increasing. Here, we evaluated the clinical outcomes post-TP. Materials and methods: Patients ( n = 41) who underwent TP between 2004 and 2011 at Tokyo Women's Medical University were retrospectively examined. Pre- and postoperative clinicophysiological data were collected up to 12 months post-TP and then analyzed. Results: Only glycated hemoglobin (HbA1c), percentage of lymphocytes and hepatic Hounsfield unit level on computed tomography (CT) were significantly different between the preoperative state and at 12 months post-TP, while other clinicophysiological parameters remained unchanged. The quantity of the pancreatic enzyme administered significantly influenced glycemic control at 12 months post-TP ( p < 0.05). Conclusions: All clinicophysiological parameters except for HbA1c were temporarily decreased after TP but normalized by 12 months. Thus, TP is a feasible surgical approach to treating pancreatic neoplasms with the potential to spread across the entire pancreas when adequately supplemented by synthetic insulin and pancreatic enzymes.